Pomerantz Law Firm Investigates Potential Securities Fraud By EyePoint, Inc. Investors Affected

Investor Alert: Investigating EyePoint, Inc.

Pomerantz LLP has initiated an investigation into EyePoint, Inc. (NASDAQ: EYPT) on behalf of its investors. This inquiry arises in response to potential allegations of securities fraud and unlawful business practices by the company and its officers. Investors who feel impacted by recent developments are encouraged to reach out for assistance.

Background of EyePoint, Inc.

EyePoint, Inc. has been at the forefront of developing pharmaceutical treatments, including products aimed at serious eye diseases. The recent release from August 17, 2026, raised alarms when the company shared results from its Phase 3 trial for DURAVYU™ (vorolanib intravitreal insert), intended for treating wet age-related macular degeneration (wet AMD).

In this announcement, it became evident that the trial had not met its expectations as the improvement in best corrected visual acuity did not surpass that of the approved treatment, aflibercept (commonly known as Eylea, made by Regeneron Pharmaceuticals). Following the negative news, EyePoint’s stock plummeted by nearly 67%, closing at just $4.87 per share, leading to significant concerns among investors.

The Role of Pomerantz LLP

Pomerantz LLP, a prominent law firm with a robust history in corporate litigation, has been advocating for victims of securities fraud and corporate misconduct since its founding over 85 years ago. With offices in major cities including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, the firm prides itself on its legacy of securing multimillion-dollar settlements for its clients in class actions.

Their investigation seeks to determine whether the leadership at EyePoint failed in their fiduciary duties to investors, particularly in light of the adverse trial results and the significant stock devaluation that followed.

Call to Action for Investors

Investors of EyePoint, Inc. are advised to reach out to Danielle Peyton at Pomerantz LLP via phone (646-581-9980, ext. 7980) or through email at [email protected]. This communication is crucial as Pomerantz prepares to take necessary legal steps against EyePoint and its executives.

It's essential for investors to remain informed and consider their legal rights in scenarios where corporate actions may lead to financial loss. Engaging with a law firm experienced in handling corporate disputes can provide clarity and direction in reclaiming losses or pursuing justice.

Conclusion

As EyePoint faces scrutiny over possible fraudulent activities, it highlights the importance of transparent communication between corporations and their investors. Keeping abreast of how the situation develops is vital for current stakeholders in EyePoint, as well as for others monitoring the market for similar risks. Investors should prioritize seeking professional advice to navigate these turbulent waters.